Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod

Aug 19(Reuters) – The U.S. Food and Drug Administration approved Ultragenyx Pharmaceutical's gene therapy to treat a rare metabolic disorder, the company said on Wednesday. (Reporting by Padmanabhan

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)